This story has been updated from a previous version.
NEW YORK, Sept. 17 – Swiss bioinformatics company GeneData said Monday it had extended its deal with Bayer to provide the pharmaceutical company with software and bioinformatics consulting services for an additional three years.
"Due to our collaboration with GeneData, we were able to increase the number of our antibacterial target candidates, at the same time significantly improving the quality of those targets,” Wolfgang Hartwig, head of pharma research at Bayer, said in a statement.
“The extended collaboration will provide the missing link between chemistry and biology, in order to obtain early decision points for novel development compounds," he added.
A spokeswoman for GeneData of Basel, Switzerland declined to provide details about the terms of the deal.
GeneData provides Bayer of Leverkusen, Germany, with is Expressionist and Phylosopher software, which are in-silico gene expression and target identification tools. Using Phylosopher, GeneData said the companies were able to develop assays for determining the function of certain targets.
To date, GeneData and Bayer said they have identified more than 150 targets for antibacterial drug discovery. The companies are hoping that their collaboration will lead to the development of new classes of antibiotics.